GlassScriptPhysician profile
Khalil M Nasrallah
NPI 1619923455
$9,076.70
in general payments reported to CMS, 2019-2025
48 companies · $195 in 2025
The $195 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,227 · 2020: $1,047 · 2021: $1,920 · 2022: $1,895 · 2023: $2,101 · 2024: $692 · 2025: $195.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,966 · Education: $21.60.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,966.20 |
| Education | $21.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $1,191.38 | 2019-2023 | Vumerity, Tysabri, Plegridy |
| Emd Serono, INC. | $1,043.73 | 2019-2024 | Mavenclad |
| Abbvie INC. | $945.63 | 2021-2025 | |
| Ucb, INC. | $606.41 | 2019-2025 | Briviact, Fintepla, Rystiggo |
| Celgene Corporation | $488.26 | 2020-2024 | Zeposia |
| Pfizer INC. | $426.67 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $385.84 | 2020-2022 | |
| Acadia Pharmaceuticals INC | $363.66 | 2019-2023 | Nuplazid |
| Allergan, INC. | $357.69 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $281.16 | 2019-2024 | |
| Alexion Pharmaceuticals, INC. | $250.04 | 2019-2022 | |
| Eisai INC. | $235.95 | 2021-2024 | |
| Janssen Pharmaceuticals, INC | $227.50 | 2019-2023 | Ponvory |
| Genentech USA, INC. | $223.82 | 2019-2023 | Ocrevus, Enspryng |
| Astrazeneca Pharmaceuticals LP | $213.21 | 2021-2024 | Andexxa |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Khalil Nasrallah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.